5:33 PM
Aug 28, 2013
 |  BC Extra  |  Clinical News

Epirus reports Phase III RA data for Remicade biosimilar

Epirus Biopharmaceuticals Inc. (Boston, Mass.) reported data on Wednesday from a Phase III trial of BOW-015, the company's biosimilar version of autoimmune drug Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and Merck & Co. Inc. (NYSE:MRK). In 189 patients with severe...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >